Trial · NCT01295827
Participant flow60
How many started, completed or left each group, period by period.
1 to 20 of 60
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A) | 4 | |
| Overall Study | STARTED | Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A) | 3 | |
| Overall Study | STARTED | Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1) | 12 | |
| Overall Study | STARTED | Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2) | 4 | |
| Overall Study | STARTED | Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2) | 3 | |
| Overall Study | STARTED | Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2) | 6 | |
| Overall Study | STARTED | MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D) | 164 | |
| Overall Study | STARTED | MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D) | 321 | |
| Overall Study | STARTED | MEL: Pembrolizumab 10 mg/kg Q2W (Part B) | 183 | |
| Overall Study | STARTED | NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F) | 61 | |
| Overall Study | STARTED | NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F) | 296 | |
| Overall Study | STARTED | NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F) | 203 | |
| Overall Study | STARTED | NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled) | 0 | |
| Overall Study | STARTED | NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled) | 0 | |
| Overall Study | STARTED | NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled) | 0 | |
| Overall Study | Treated (All Treated Population) | Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A) | 4 | |
| Overall Study | Treated (All Treated Population) | Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A) | 3 | |
| Overall Study | Treated (All Treated Population) | Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1) | 10 | |
| Overall Study | Treated (All Treated Population) | Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2) | 4 | |
| Overall Study | Treated (All Treated Population) | Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2) | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01295827/flow